01/10/2026
Wound care innovation is accelerating—and the focus is shifting from “what works” to what works, for whom, and supported by what evidence. The tissue technology leader, 𝙏𝙞𝙜𝙚𝙧 𝘽𝙞𝙤𝙎𝙘𝙞𝙚𝙣𝙘𝙚𝙨, that my company is partnered with is leading the way.
A recent piece highlights how 𝙏𝙞𝙜𝙚𝙧 𝘽𝙞𝙤𝙎𝙘𝙞𝙚𝙣𝙘𝙚𝙨 is leaning into a data-driven approach at the International Post-Acute Wound Care Society Summit (IPAWS), including five peer-reviewed retrospective manuscripts in 2024 and ongoing randomized controlled trials evaluating ACApatch and caregraFT alongside standard care for VLUs, DFUs, and pressure ulcers.
For clinicians and post-acute leaders, it’s a timely reminder: real-world evidence + rigorous trials + collaboration are key to improving outcomes in complex wounds.
Read the article here: https://www.msn.com/en-us/health/other/inside-the-growing-race-to-transform-wound-care-innovation/ar-AA1QX6bE
CONSHOHOCKEN, PA — Tiger BioSciences positioned itself at the center of the wound care industry’s latest scientific discussions as the headline sponsor of the International Post-Acute Wound Care Society Summit …